Literature DB >> 26408715

Survival After Distant Metastasis in Head and Neck Cancer.

Susanne Wiegand1, Annette Zimmermann2, Thomas Wilhelm2, Jochen A Werner2.   

Abstract

BACKGROUND/AIM: In addition to locoregional recurrence distant metastases can limit the survival of patients with head and neck cancer. The aim of the study was to analyze survival after distant metastasis of head and neck cancer. PATIENTS AND METHODS: Patients with head and neck cancer and M0 status at initial diagnosis, who were treated with curative intent but developed distant metastases without synchronous locoregional recurrence were analyzed. Predictors for the duration of survival were evaluated using Cox regression analysis.
RESULTS: A total of 46 patients developed distant metastases which were detected after a mean time of 16 months, most were lung (59%) and bone metastases (24%). The most common therapy for distant metastasis was palliative chemotherapy; due to poor general condition, 21% of patients were treated with best supportive care. The mean survival was 7.5 months, the overall survival at 1 and 2 years after diagnosis of distant metastasis were 40.4% and 26.2%, respectively. Regression analysis showed no significant predictors for prolonged survival, however, the three patients surviving at the time of data collection were treated by surgical resection of solitary metastases.
CONCLUSION: In cases of distant metastases, due to poor prognosis of the patients, palliation is important and the treatment approach should be chosen taking into account the general condition of the patient. In individual cases, resection of solitary metastases may be useful. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Head and neck cancer; bone metastasis; distant metastasis; lung metastasis; survival

Mesh:

Year:  2015        PMID: 26408715

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful?

Authors:  Jefree J Schulte; Jamie Steinmetz; Larissa V Furtado; Aliya N Husain; Mark W Lingen; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2020-04-29

2.  MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.

Authors:  Ofra Novoplansky; Matthew Fury; Manu Prasad; Ksenia Yegodayev; Jonathan Zorea; Limor Cohen; Raphael Pelossof; Liz Cohen; Nora Katabi; Fabiola Cecchi; Ben-Zion Joshua; Aron Popovtzer; Jose Baselga; Maurizio Scaltriti; Moshe Elkabets
Journal:  Int J Cancer       Date:  2019-02-11       Impact factor: 7.396

3.  Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.

Authors:  Mai Badarni; Manu Prasad; Noa Balaban; Jonathan Zorea; Ksenia M Yegodayev; Ben-Zion Joshua; Anat Bahat Dinur; Reidar Grénman; Barak Rotblat; Limor Cohen; Moshe Elkabets
Journal:  JCI Insight       Date:  2019-03-12

4.  Application of circulating tumour cells to predict response to treatment in head and neck cancer.

Authors:  Xi Zhang; Chameera Ekanayake Weeramange; Brett G M Hughes; Sarju Vasani; Zhen Yu Liu; Majid Ebrahimi Warkiani; Gunter Hartel; Rahul Ladwa; Jean Paul Thiery; Liz Kenny; Chamindie Punyadeera
Journal:  Cell Oncol (Dordr)       Date:  2022-06-23       Impact factor: 7.051

Review 5.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

6.  Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.

Authors:  Sun Min Lim; Min Hee Hong; Sang-Jun Ha; Daehee Hwang; Sehyun Chae; Yoon Woo Koh; Eun Chang Choi; Se-Heon Kim; Da-Hee Kim; Sun Och Yoon; Hye Ryun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-22       Impact factor: 4.553

7.  Neuropeptide Substance P Enhances Inflammation-Mediated Tumor Signaling Pathways and Migration and Proliferation of Head and Neck Cancers.

Authors:  Sumeet Singh; Subhashree Kumaravel; Saurabh Dhole; Sukanya Roy; Vani Pavan; Sanjukta Chakraborty
Journal:  Indian J Surg Oncol       Date:  2020-09-01

8.  Solitary adrenal metastasis from salivary duct carcinoma of the parotid gland successfully treated by surgery: A case report.

Authors:  Yusuke Amano; Kentaro Tsuji; Atshushi Kihara; Daisuke Matsubara; Noriyoshi Fukushima; Hiroshi Nishino; Toshiro Niki
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

9.  The Clinical Characteristics and Prognostic Nomogram for Head and Neck Cancer Patients with Bone Metastasis.

Authors:  Changxing Chi; Zhiyi Fan; Binbin Yang; He Sun; Zengpai Zheng
Journal:  J Oncol       Date:  2021-09-27       Impact factor: 4.375

10.  Cancer recurrence times from a branching process model.

Authors:  Stefano Avanzini; Tibor Antal
Journal:  PLoS Comput Biol       Date:  2019-11-21       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.